Filing Flows › Roivant Sciences (ROIV) › Q2 FY27 › vs Q1 FY27
Roivant Sciences (ROIV) Q2 FY27 vs Q1 FY27 (quarter over quarter)
Roivant Sciences's revenue rose $33.7M (24×) from $1.4M in Q1 FY27 to $35.1M in Q2 FY27.
Roivant Sciences, Q2 FY27: revenue $35.1M (22× year over year), operating margin -763.2%, net loss $137M, operating cash flow $594M. The chart draws each line against Q1 FY27, the increases inside each band.
Every line
| Line | Q2 FY27 | Q1 FY27 | Change | % |
|---|---|---|---|---|
| Revenue | $35.1M | $1.4M | $33.7M | 24× |
| Other income, net | $117M | $71.4M | $46.0M | +64% |
| Income tax benefit | $13.4M | $4.0M | $9.4M | +238% |
| Net loss | $137M | $291M | −$153M | -53% |
| Costs & expenses | $303M | $367M | −$64.3M | -17% |
| Operating costs | $303M | $367M | −$64.3M | -17% |
| Research & development | $146M | $202M | −$56.3M | -28% |
| Operating cash sources | $732M | $20.1M | $712M | 36× |
| Depreciation & amortization | $604K | $600K | $4K | +0.7% |
| Share-based compensation | $79.3M | $83.3M | −$4.0M | -5% |
| Working capital & other | $652M | −$63.8M | $716M | — |
| Net loss absorbed | $137M | $291M | −$153M | -53% |
| Operating cash flow | $594M | −$271M | $865M | — |
| Free cash flow (OCF − capex) | $594M | −$271M | $865M | — |
| Capital expenditures | $208K | $419K | −$211K | -50% |
Questions
How much did Roivant Sciences's revenue grow quarter over quarter in Q2 FY27?
Roivant Sciences's revenue rose $33.7M (24×) from $1.4M in Q1 FY27 to $35.1M in Q2 FY27.